346 related articles for article (PubMed ID: 28317560)
1. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
3. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
4. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
5. Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
Seagle BL; Dayno M; Strohl AE; Graves S; Nieves-Neira W; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):472-478. PubMed ID: 27760707
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
7. Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study.
Versluis MAC; Pielsticker C; van der Aa MA; de Bruyn M; Hollema H; Nijman HW
Oncology; 2018; 95(2):100-108. PubMed ID: 29791913
[TBL] [Abstract][Full Text] [Related]
8. Vaginal brachytherapy for early-stage carcinosarcoma of the uterus.
Brown LC; Petersen IA; Haddock MG; Bakkum-Gamez JN; Lee LJ; Cimbak NC; Berkowitz RS; Viswanathan AN
Brachytherapy; 2015; 14(4):433-9. PubMed ID: 25890795
[TBL] [Abstract][Full Text] [Related]
9. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
[TBL] [Abstract][Full Text] [Related]
10. Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.
Seagle BL; Kanis M; Strohl AE; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):636-641. PubMed ID: 27771166
[TBL] [Abstract][Full Text] [Related]
11. Black race independently predicts worse survival in uterine carcinosarcoma.
Erickson BK; Doo DW; Zhang B; Huh WK; Leath CA
Gynecol Oncol; 2014 May; 133(2):238-41. PubMed ID: 24613675
[TBL] [Abstract][Full Text] [Related]
12. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
13. Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases.
Grasso S; Loizzi V; Minicucci V; Resta L; Camporeale AL; Cicinelli E; Cormio G
Oncology; 2017; 92(4):197-204. PubMed ID: 28092915
[TBL] [Abstract][Full Text] [Related]
14. Ovarian granulosa cell tumor: A National Cancer Database study.
Seagle BL; Ann P; Butler S; Shahabi S
Gynecol Oncol; 2017 Aug; 146(2):285-291. PubMed ID: 28532858
[TBL] [Abstract][Full Text] [Related]
15. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis.
Nemani D; Mitra N; Guo M; Lin L
Gynecol Oncol; 2008 Oct; 111(1):82-8. PubMed ID: 18674808
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis.
Stokes WA; Robin TP; Jackson MW; Amini A; Schefter TE; Lefkowits CC; Fisher CM
Am J Clin Oncol; 2018 Oct; 41(10):927-932. PubMed ID: 28654573
[TBL] [Abstract][Full Text] [Related]
17. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
18. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
[TBL] [Abstract][Full Text] [Related]
19. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis.
Rauh-Hain JA; Starbuck KD; Meyer LA; Clemmer J; Schorge JO; Lu KH; Del Carmen MG
Gynecol Oncol; 2015 Oct; 139(1):84-9. PubMed ID: 26307402
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).
Cha J; Kim YS; Park W; Kim HJ; Kim JY; Kim JH; Kim J; Yoon WS; Kim JW; Kim YB
J Gynecol Oncol; 2016 Nov; 27(6):e58. PubMed ID: 27550404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]